R A Pacis1, M J Pilat, K J Pienta, K Wojno, A Raz, V Hogan, C R Cooper. 1. University of Michigan Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Internal Medicine, St. John's Hospital, Detroit, Michigan, USA.
Abstract
BACKGROUND: Galectin-3 is a carbohydrate-binding protein whose level of expression has been shown to be correlated with metastatic potential in a number of different tumor types. The purpose of this investigation was to examine galectin-3 expression in several tumorigenic and nontumorigenic prostate cell lines and prostate tissue samples. METHODS: The expression of galectin-3 in cell lines and tissue samples was evaluated by tissue immunohistochemistry and Western blot analysis. RESULTS: Human cell lines PC-3M, PC-3, DU-145, PrEC-1, and MCF10A demonstrated the presence of galectin-3. Galectin-3 was not detected in TSU-pr1 and LNCaP by Western blot analysis. We furthered our studies by examining a series of human prostate tissue samples for expression of galectin-3. Overall, approximately 60-70% of the normal tissue examined demonstrated heterogenous expression of galectin-3. In stage II tumors, however, there was a dramatic decrease in galectin-3 expression in both PIN and tumor sections, with only 10.5% (2/19) of these samples expressing this protein. Stage III tumors also demonstrated a decreased expression of galectin-3, although this downregulation was not as dramatic, with 35% of PIN samples and 52% of tumor tissue expressing galectin-3 (P < 0.01). CONCLUSIONS: These data demonstrate that galectin-3 is downregulated in prostate cancer. The altered downregulation pattern of galectin-3 observed between tumor stages suggests different roles for galectin-3 in the progression of prostate cancer. Copyright 2000 Wiley-Liss, Inc.
BACKGROUND:Galectin-3 is a carbohydrate-binding protein whose level of expression has been shown to be correlated with metastatic potential in a number of different tumor types. The purpose of this investigation was to examine galectin-3 expression in several tumorigenic and nontumorigenic prostate cell lines and prostate tissue samples. METHODS: The expression of galectin-3 in cell lines and tissue samples was evaluated by tissue immunohistochemistry and Western blot analysis. RESULTS:Human cell lines PC-3M, PC-3, DU-145, PrEC-1, and MCF10A demonstrated the presence of galectin-3. Galectin-3 was not detected in TSU-pr1 and LNCaP by Western blot analysis. We furthered our studies by examining a series of human prostate tissue samples for expression of galectin-3. Overall, approximately 60-70% of the normal tissue examined demonstrated heterogenous expression of galectin-3. In stage II tumors, however, there was a dramatic decrease in galectin-3 expression in both PIN and tumor sections, with only 10.5% (2/19) of these samples expressing this protein. Stage III tumors also demonstrated a decreased expression of galectin-3, although this downregulation was not as dramatic, with 35% of PIN samples and 52% of tumor tissue expressing galectin-3 (P < 0.01). CONCLUSIONS: These data demonstrate that galectin-3 is downregulated in prostate cancer. The altered downregulation pattern of galectin-3 observed between tumor stages suggests different roles for galectin-3 in the progression of prostate cancer. Copyright 2000 Wiley-Liss, Inc.
Authors: Sarika Saraswati; Ashley S Block; Mari K Davidson; Roger G Rank; Maha Mahadevan; Alan B Diekman Journal: Prostate Date: 2011-02-01 Impact factor: 4.104
Authors: Afshin Teymoortash; Anna Pientka; Carsten Schrader; Markus Tiemann; Jochen A Werner Journal: J Cancer Res Clin Oncol Date: 2005-09-24 Impact factor: 4.553
Authors: Yi Wang; Pratima Nangia-Makker; Larry Tait; Vitaly Balan; Victor Hogan; Kenneth J Pienta; Avraham Raz Journal: Am J Pathol Date: 2009-03-12 Impact factor: 4.307
Authors: Prasun Guha; Engin Kaptan; Gargi Bandyopadhyaya; Sabina Kaczanowska; Eduardo Davila; Keyata Thompson; Stuart S Martin; Dhananjaya V Kalvakolanu; Gerardo R Vasta; Hafiz Ahmed Journal: Proc Natl Acad Sci U S A Date: 2013-03-11 Impact factor: 11.205